Table 1.
Study Population Characteristics (n=350)
| n (%) | |
|---|---|
| Age (y), mean (SD) | 9.8 (3.2) |
| Male gender | 218 (63.2) |
| Race | |
| Black/African American | 278 (79.4) |
| White | 36 (10.3) |
| Other or Unknown | 36 (10.3) |
| Hispanic ethnicity | 75 (21.4) |
| Socioeconomic Measures | |
| Public insurance | 303 (87.8) |
| Annual income < $30K | 232 (66.3) |
| Study Site | |
| Baltimore | 239 (68.3) |
| Boston | 111 (31.7) |
| Asthma-related Acute Visits and Hospitalizations, last 3 months | |
| Acute (ED, urgent care, unscheduled PCP) visit | 234 (66.9) |
| Hospitalization | 44 (12.6) |
| Asthma Controller Medication (n=326) | |
| Step 1: Short acting β-agonist as needed | 38 (11.7) |
| Step 2: Low-dose inhaled corticosteroids (ICS) or leukotriene modifier | 61 (18.7) |
| Step 3: Low-dose ICS plus long acting β-agonist or medium-dose ICS | 49 (15.0) |
| Step 4: Medium-dose ICS plus long acting β-agonist | 16 (4.9) |
| Step 5: High dose ICS with or without long acting β-agonist | 162 (49.7) |
| Lung Physiology (Pre-BD) | |
| FEV1 % predicted, mean (SD)* | 87.1 (17.3) |
| FEV1 < 80% predicted* | 65 (30.8) |
| FVC % predicted, mean (SD)* | 96.8 (16.2) |
| FEV1/FVC%^ | 80.2 (9.0) |
| FEV1/FVC% < 85%^ | 211 (64.3) |
| Skin Prick Test (SPT) Sensitization (n=297) | |
| ≥1 +SPT | 291 (98.0) |
| No. +SPTs, mean (SD) | 6.1 (3.2) |
| Cockroach | 162 (54.6) |
| Cat | 159 (53.5) |
| Dust mite | 132 (44.4) |
| Dog | 67 (22.6) |
| Allergen bedroom floor level | |
| Mouse (μg/g), median (25th-75th%ile) | 5.7 (1.5–22.8) |
| ≥75% mean reduction from baseline | 92 (26.3) |
*
restricted to ≥8y, n=211; ^n=328